Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics, Inc.

Biotechnology • Healthcare • Ponte Vedra, FL, United States • CVKD (NCM)

Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company focuses on developing therapeutics for rare cardiovascular conditions. The company is developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. It has a collaboration agreement with Abbott Global Enterprises Limited to evaluate the efficacy and safety of Tecarfarin in patients with a left-ventricular assist device. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

904 300 0701 822 A1A North, Ponte Vedra, FL 32082, United States

Stock Performance (90 Days)

Data through Dec 29, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Inside the drug startup rebuilding blood thinners for medicine’s toughest cases - Stock Titan
Stock Titan • Dec 29
Cadrenal Therapeutics, Inc. - Yahoo Finance
Yahoo Finance • Nov 7
Cadrenal Therapeutics Expands At-The-Market Stock Offering Capacity - TipRanks
TipRanks • Dec 23
Cadrenal Therapeutics, Inc. Reports Q3 2025 Financial Results and Clinical Development Updates on Tecarfarin and Frunexian - Quiver Quantitative
Quiver Quantitative • Nov 10
Cadrenal Therapeutics announces new securities purchase agreement - MSN
MSN • Dec 23

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has Cadrenal Therapeutics, Inc. had layoffs?
No layoff events have been recorded for Cadrenal Therapeutics, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does Cadrenal Therapeutics, Inc. have?
Cadrenal Therapeutics, Inc. has approximately 4 employees.
What industry is Cadrenal Therapeutics, Inc. in?
Cadrenal Therapeutics, Inc. operates in the Biotechnology industry, within the Healthcare sector.
Is Cadrenal Therapeutics, Inc. a publicly traded company?
Yes, Cadrenal Therapeutics, Inc. is publicly traded under the ticker symbol CVKD on the NCM. The company has a market capitalization of approximately $0.02 billion.
Where is Cadrenal Therapeutics, Inc. headquartered?
Cadrenal Therapeutics, Inc. is headquartered in Ponte Vedra, FL, United States at 822 A1A North, Ponte Vedra, FL 32082, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.